Hoth Therapeutics Announces Key Developments in HT-KIT Cancer Fighting Drug Candidate
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on pioneering therapies for allergic and inflammatory diseases, today revealed two significant advancements in the development of its proprietary antisense oligonucleotide (ASO) cancer-fighting drug candidate, HT-KIT. The company has filed amended claims with the U.S. Patent and Trademark Office to further strengthen the intellectual property protection […]